LL-37 for Biofilm Disruption in Chronic Lyme
How LL-37 disrupts Borrelia biofilms in chronic Lyme disease. Mechanism, preclinical evidence, protocol context, and clinical observations.
Peptide Therapy
Emerging EvidenceLL-37
Human cathelicidin antimicrobial peptide for biofilm disruption and innate immune defense.
01
02
LL-37 and Vitamin D: The Immune Connection
How vitamin D regulates LL-37 production and why this matters for immunity. The cathelicidin pathway, optimal levels, and clinical implications.
03
LL-37: The Antimicrobial Peptide for Innate Immunity
LL-37 antimicrobial peptide review by Dr. Julian Douwes. Innate immunity, biofilm disruption, Lyme disease applications, and clinical perspective.
